Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 443-446 (mars 2008)
Doi : 10.1016/j.jaad.2007.11.011

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

Lily Clark, MD a, Mark Lebwohl, MD b,
a Department of Dermatology at Columbia University, New York, New York 
b Department of Dermatology at Mount Sinai School of Medicine, New York, New York 

Reprint requests: Mark Lebwohl, MD, Department of Dermatology, Mount Sinai School of Medicine, 5 E 98th St, 5th Floor, New York, NY 10029.

The prevalence of obesity is rapidly increasing in the United States. Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight.


We attempted to determine whether the efficacy of the biologics is affected by weight.


We review the existing body of literature, including subgroup analyses, relating to efficacy and weight for infliximab, efalizumab, alefacept, and etanercept. No relevant literature was found for adalimumab.


Weight-based dosed medications do not seem to lose efficacy with increasing weight. Both etanercept and alefacept may have compromised efficacy in heavier individuals.


The data are limited to subgroup analyses and smaller studies, often with no statistical significance reported.


Additional studies are warranted, specifically designed to address the issue of obesity and response to therapy of the biologics. Alternative dosing for etanercept and alefacept should be further evaluated in patients above normal weight

The full text of this article is available in PDF format.

Abbreviations used : BMI, FDA, PASI, SC, TNF

 Funding sources: None.
 Disclosure: In the last 12 months, members of Dr Lebwohl’s department have served at the drug companies listed below. Dr Lebwohl is also a consultant (or has pending agreements) for Abbott, Amgen, Astellas, Biogen Idec, Centocor, Connetics, Genentech, Novartis, Pfizer, Warner Chilcott, and 3M. In addition, members of Mount Sinai’s Department of Dermatology hold patents for short-contact tazarotene therapy, excimer laser treatment vitiligo, and topical genistein. Finally, in the last 12 months, Dr Lebwohl has served as speaker for Abbott, Allergan, Amgen, Astellas, Biogen Idec, Centocor, Connetics, Novartis, Warner Chilcott, and 3M. Dr Clark has no conflicts of interest to declare.

© 2008  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline